Zelda Therapeutics makes significant progress in medicinal cannabis research programs
By Administrator | 4 May 2018
Listed medicinal cannabis company Zelda Therapeutics (ASX: ZLD) has made progress in a number of key research programs during the March 2018 financial quarter.
Zelda recently received approval for a major study into the pharmacology of cannabinoids in the treatment of paediatric autism patients.
The study is set to be conducted at the USA-based Children's Hospital of Philadelphia, and Zelda says it is a key milestone in ongoing medical cannabis research in a clinical environment.
The group has also expanded its pre-clinical pancreatic cancer research programme with Curtin University.
The study focuses on live animal studies to investigate the effect of a range of the group's formulations in combination with existing chemotherapy agents.
Zelda says animal research is a major precursor to future human clinical trials.
During the last quarter, the group announced the initiation of a new pre-clinical research programme exploiting the potential for certain cannabinoids formulations to reduce the impact of diabetes-associated cognitive decline. Read more
David Simmons - Business News Australia - 30 April 2018
Comments
Your email address will not be published.
We welcome relevant, respectful comments.